, Volume 18, Issue 1, pp 1–8 | Cite as

Novel Strategies for the Prevention of Bypass Graft Failure

Novel Therapeutic Strategies


Bypass vein graft disease remains a significant limitation to the care of millions of patients with ischemic disease of the heart and lower extremities. The pathogenesis of this rapid, aggressive, occlusive disease lies in the remodeling response of the grafts themselves to the new arterial environment. As such, the molecular and cellular biology of neointimal hyperplasia provides a unique opportunity for cardiovascular researchers to more closely model a human clinical entity from its inception to the development of advanced disease. Recent years have therefore seen a broad new array of possible interventions for vein graft disease based on a sophisticated translation of genetic and molecular science. One of these applications, E2F decoys, has already progressed to phase III clinical studies, and many others will likely follow as the tools for therapeutic translation continue to improve. These include both gene transfer and gene blockade strategies.


Vascular Smooth Muscle Cell Vein Graft Neointimal Hyperplasia Neointimal Formation Vascular Smooth Muscle Cell Proliferation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The author has a financial interest in Corgentech Inc., which owns the rights to and is leading the clinical development of E2F decoy treatment of bypass vein grafts.


  1. 1.
    Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol 1996; 28: 616–26PubMedCrossRefGoogle Scholar
  2. 2.
    Campeau L, Enjalbert M, Lesperance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of diseasein the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311: 1329–34PubMedCrossRefGoogle Scholar
  3. 3.
    Grondin CM. Late results of coronary artery grafting: is there a flag on the field? J Thorac Cardiovasc Surg 1984; 87: 161–6PubMedGoogle Scholar
  4. 4.
    Reardon MJ, Conklin LD, Reardon PR, et al. Coronary artery bypass conduits: review of current status. J Cardiovasc Surg 1997; 97: 916–31Google Scholar
  5. 5.
    Campeau L. Lipid lowering and coronary bypass graft surgery. Curr Opin Cardiol 2000; 15: 395–9PubMedCrossRefGoogle Scholar
  6. 6.
    Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimai hyperplasia. J Vasc Surg 1991; 13: 885–90PubMedCrossRefGoogle Scholar
  7. 7.
    Cox JL, Chaisson DA, Gotleib AI. Stranger in a strange land: the pathogeneis of saphenous vein graft stenosis. Prog Cardiovasc Dis 1991; 34: 45–68PubMedCrossRefGoogle Scholar
  8. 8.
    Kohler TR, Kirkman TR, Gordon D, et al. Mechanism of long-term degeneration of arterialized vein grafts. Am J Surg 1990; 160: 257–61PubMedCrossRefGoogle Scholar
  9. 9.
    Clinton SK, Libby P. Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 1992; 116: 1292–300PubMedGoogle Scholar
  10. 10.
    Faries PL, Marin ML, Veith FJ, et al. Immunolocalization and temporal distribution of cytokine expression during the development of vein graft intimai hyperplasia in an experimental model. J Vasc Surg 1996; 24: 463–71PubMedCrossRefGoogle Scholar
  11. 11.
    Hoch JR, Stark VK, Hullett DA, et al. Vein graft intimai hyperplasia: leukocytes and cytokine expression. Surgery 1994; 116: 463–71PubMedGoogle Scholar
  12. 12.
    Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg 1987; 5: 126–36PubMedGoogle Scholar
  13. 13.
    Tanaka H, Sukhova GK, Swanson SJ, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 1993; 88: 1788–803PubMedCrossRefGoogle Scholar
  14. 14.
    Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 1990; 85:731–8PubMedCrossRefGoogle Scholar
  15. 15.
    Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181–9PubMedCrossRefGoogle Scholar
  16. 16.
    Chester AH, O’Neil GS, Moncada S, et al. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet 1990; 336: 897–900PubMedCrossRefGoogle Scholar
  17. 17.
    Bossaller C, Habib GB, Yamamoto H, et al. Impaired muscarinic endotheliumdependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 1987; 79: 170–4PubMedCrossRefGoogle Scholar
  18. 18.
    Ku DD, Caulfield JB, Kirklin JK. Endothelium-dependent responses in long-term human coronary artery bypass grafts. Circulation 1991; 83: 402–11PubMedCrossRefGoogle Scholar
  19. 19.
    Weidinger FF, McLenachan JM, Cybulsky M, et al. Persistent dysfunction of regenerated endothelium following balloon angioplasty of rabbit iliac artery. Circulation 1990; 81: 1667–79PubMedCrossRefGoogle Scholar
  20. 20.
    Park TC, Harker CT, Edwards JM, et al. Human saphenous vein grafts explanted from the arterial circulation demonstrate altered smooth-muscle and endothelial responses. J Vasc Surg 1993; 18: 61–9PubMedCrossRefGoogle Scholar
  21. 21.
    Cross KS, El-Sanadiki MN, Murray JJ, et al. Functional abnormalities of experimental autologous vein graft neoendothelium. Ann Surg 1988; 208: 631–8PubMedCrossRefGoogle Scholar
  22. 22.
    Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998 Jul 7; 98(1): 82–9PubMedCrossRefGoogle Scholar
  23. 23.
    Zwolak RM, Kirkman TR, Clowes AW. Atherosclerosis in rabbit vein grafts. Arteriosclerosis 1989; 9: 374–9PubMedCrossRefGoogle Scholar
  24. 24.
    Conte MS, Mann MJ, Simosa HF, et al. Genetic interventions for vein bypass graft disease: a review. J Vasc Surg 2002 Nov; 36(5): 1040–52PubMedCrossRefGoogle Scholar
  25. 25.
    Colman A. Antisense strategies in cell and developmental biology. J Cell Sci 1990; 97: 399–409PubMedGoogle Scholar
  26. 26.
    Hannon GJ. RNA interference. Nature 2002; 418: 244–51PubMedCrossRefGoogle Scholar
  27. 27.
    Zaug A, Been M, Cech T. The tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature 1986; 324: 429–33PubMedCrossRefGoogle Scholar
  28. 28.
    Bielinska A, Schivdasani RA, Zhang L, et al. Regulation of gene expression with double-stranded phosphothioate oligonucleotides. Science 1990; 250: 997–1000PubMedCrossRefGoogle Scholar
  29. 29.
    Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A 1993; 90: 8474–8PubMedCrossRefGoogle Scholar
  30. 30.
    Mann MJ, Gibbons GH, Kernoff RS, et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A 1995; 92: 4502–6PubMedCrossRefGoogle Scholar
  31. 31.
    Gaubatz S, Wood JG, Livingston DM. Unusual proliferation arrest and transcriptional control properties of a newly discovered E2F family member, E2F-6. Proc Natl Acad Sci U S A 1998; 95: 9190–5PubMedCrossRefGoogle Scholar
  32. 32.
    Morishita R, Gibbons GH, Horiuchi M, et al. A novel molecular strategy using cis element ‘decoy’ of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995; 92: 5855–9PubMedCrossRefGoogle Scholar
  33. 33.
    Ehsan A, Mann MJ, Dell’ Acqua G, et al. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001; 121: 714–22PubMedCrossRefGoogle Scholar
  34. 34.
    Mann MJ, Gibbons GH, Tsao PS, et al. Cell cycle inhibition preserves endothelial function in genetically engineered vein grafts. J Clin Invest 1997; 99: 1295–301PubMedCrossRefGoogle Scholar
  35. 35.
    Mann MJ, Whittemore AD, Donaldson MC, et al. Ex vivo gene therapy for human bypass vein grafts: the PREVENT single centre randomised clinical trial. Lancet 1999; 354: 1493–8PubMedCrossRefGoogle Scholar
  36. 36.
    Mann MJ, Gibbons GH, Poston R, et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A 1999; 96: 6411–6PubMedCrossRefGoogle Scholar
  37. 37.
    Grube E, Felderhoff T, Fitzgerald PJ, et al. Genetic manipulation of human coronary artery bypass grafts with E2F decoy (GT003) reduces clinical graft failure: results of the randomized, controlled PREVENT II trial. Late-breaking Clinical Trials Session, American Heart Association Scientific Sessions; 2001 Nov 12; Anaheim, CaliforniaGoogle Scholar
  38. 38.
    Chen S-J, Wilson JM, Muller DWM. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation 1994; 89: 1922–8PubMedCrossRefGoogle Scholar
  39. 39.
    Chiu-Pinheiro CK, O’Brien T, Katusic ZS, et al. Gene transfer to coronary artery bypass conduits. Ann Thorac Surg 2002; 74: 1161–6PubMedCrossRefGoogle Scholar
  40. 40.
    Skelly CL, Curi MA, Meyerson SL, et al. Prevention of restenosis by a herpes simplex virus mutant capable of controlled long-term expression in vascular tissue in vivo. Gene Ther 2001; 8: 1840–6PubMedCrossRefGoogle Scholar
  41. 41.
    Kupfer JM, Ruan XM, Liu G, et al. High efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine-DNA complexes. Hum Gene Ther 1994; 5: 1437–43PubMedCrossRefGoogle Scholar
  42. 42.
    George SJ, Johnson JL, Angelini GD, et al. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998; 9: 867–77PubMedCrossRefGoogle Scholar
  43. 43.
    George SJ, Baker AH, Angelini GD, et al. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 1998; 5(11): 1552–60PubMedCrossRefGoogle Scholar
  44. 44.
    George SJ, Lloyd CT, Angelini GD, et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000; 101: 296–304PubMedCrossRefGoogle Scholar
  45. 45.
    Bai H, Morishita R, Kida I, et al. Inhibition of intimai hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther 1998; 5(6): 761–9PubMedCrossRefGoogle Scholar
  46. 46.
    Ohno N, Itoh H, Ikeda T, et al. Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 2002; 105: 1623–6PubMedCrossRefGoogle Scholar
  47. 47.
    Ohta S, Komori K, Yonemitsu Y, et al. Intraluminal gene transfer of endothelial cell-nitric oxide synthase suppresses intimai hyperplasia of vein grafts in cholesterol-fed rabbit: a limited biological effect as a result of the loss of medial smooth muscle cells. Surgery 2002; 131: 644–53PubMedCrossRefGoogle Scholar
  48. 48.
    Kibbe MR, Tzeng E, Gleixner SL, et al. Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimai hyperplasia. J Vasc Surg 2001; 34: 156–65PubMedCrossRefGoogle Scholar
  49. 49.
    Curi MA, Skelly CL, Meyerson SL, et al. Sustained inhibition of experimental neointimal hyperplasia with a genetically modified herpes simplex virus. J Vasc Surg 2003 Jun; 37(6): 1294–300PubMedCrossRefGoogle Scholar
  50. 50.
    Mayr U, Mayr M, Li C, et al. Loss of p53 accelerates neointimal lesions of vein bypass grafts in mice. Circ Res 2002; 90: 197–204PubMedCrossRefGoogle Scholar
  51. 51.
    Pollman MJ, Hall JL, Mann MJ, et al. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 1998; 4: 222–7PubMedCrossRefGoogle Scholar
  52. 52.
    Shoji T, Yonemitsu Y, Komori K, et al. Intramuscular gene transfer of FGF-2 attenuates endothelial dysfunction and inhibits intimai hyperplasia of vein grafts in poor-runoff limbs of rabbit. Am J Physiol Heart Circ Physiol 2003 Jul; 285(1): H173–82PubMedGoogle Scholar
  53. 53.
    Shintani T, Sawa Y, Takahashi T, et al. Intraoperative transfection of vein grafts with the NFkappaB decoy in a canine aortocoronary bypass model: a strategy to attenuate intimai hyperplasia. Ann Thorac Surg 2002 Oct; 74(4): 1132–7PubMedCrossRefGoogle Scholar
  54. 54.
    Angelini GD, Lloyd C, Bush R, et al. An external, oversized, porous polyester stent reduces vein graft neointima formation, cholesterol concentration, and vascular cell adhesion molecule 1 expression in cholesterol-fed pigs. J Thorac Cardiovasc Surg 2002 Nov; 124(5): 950–6PubMedCrossRefGoogle Scholar
  55. 55.
    Huynh TT, Davies MG, Thompson MA, et al. Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimai hyperplasia in experimental vein grafts. J Vasc Surg 2001 Feb; 33(2): 400–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Division of Cardiothoracic SurgeryUCSF Medical CenterSan FranciscoUSA

Personalised recommendations